Viewing data from:

FYAVOLV

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | A204213 | LUPIN LTD

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Fyavolv (2023)

Total Spending

$809K

Total Claims

8,184

Beneficiaries

2,379

Avg Cost/Unit

$1.56

Spending Trend

$895K(2019)→$957K(2020)→$853K(2021)→$848K(2022)→$809K(2023)

YoY Change:-12.7%

5yr CAGR:-5.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (2)

Sort:

#001 — 0.0025MG;0.5MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Dec 10, 2015

No patent or exclusivity listings for this strength.

#002 — 0.005MG;1MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Dec 10, 2015